Covid-19: a first step towards commercialization for Merck’s miracle pill?

The European Medicines Agency (EMA) has launched the continuous review of molnupiravir, the COVID-19 pill developed by Merck, the US pharmaceutical group said on Monday.

The continuous review procedure allows the AEM to study the data on the safety and efficacy of treatments as they appear and to speed up the assessment of a formal application for marketing authorization. .
Merck has already filed on October 11 an emergency approval request with the American health authority, the Food and Drug Administration (FDA), for this experimental antiviral pill.
If approved, this pill would provide the first oral COVID-19 treatment and also the first treatment for patients with mild or moderate symptoms of the disease, while existing treatments are used for more severe cases. serious.


Covid19 step commercialization Mercks miracle pill

For Latest Updates Follow us on Google News

PREV WHO calls for vaccine against bacteria that kill 150,000 babies per year
NEXT Study: Corona vaccinated people with breakthrough vaccination similarly contagious as unvaccinated people